Glaukos Corporation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$60.7M
Doctors Paid
17,708
Transactions
69,190
2024 Total
$11.4M
Payment Breakdown by Category
Research$43.5M (71.7%)
Consulting$7.4M (12.2%)
Food & Beverage$3.2M (5.2%)
Royalty/License$693,689 (1.1%)
Travel$502,447 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43.5M | 16,903 | 71.7% |
| Consulting Fee | $7.4M | 2,419 | 12.2% |
| Food and Beverage | $3.2M | 47,719 | 5.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 326 | 2.9% |
| Current or prospective ownership or investment interest | $1.4M | 9 | 2.2% |
| Honoraria | $1.0M | 717 | 1.7% |
| Royalty or License | $693,689 | 10 | 1.1% |
| Travel and Lodging | $502,447 | 723 | 0.8% |
| Grant | $374,363 | 79 | 0.6% |
| Education | $335,971 | 80 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $280,898 | 130 | 0.5% |
| Long term medical supply or device loan | $265,957 | 38 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $26,000 | 25 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $8,500 | 8 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,250 | 3 | 0.0% |
| Debt forgiveness | $17.00 | 1 | 0.0% |
Payments by Type
Research
$43.5M
16,896 transactions
General
$17.2M
52,287 transactions
Ownership
$0
7 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 | $7.7M | 34 | 2,248 |
| Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% | $6.0M | 20 | 2,730 |
| A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus | $3.9M | 0 | 1,597 |
| A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery | $3.1M | 5 | 1,519 |
| A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study of the Glaukos iStent Trabecular Micro-Bypass Stent System in Conjunction with Cataract Surgery | $2.5M | 2 | 754 |
| iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | $2.4M | 4 | 692 |
| Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects with Open-angle Glaucoma or Ocular Hypertension | $2.0M | 0 | 281 |
| Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5% | $1.7M | 3 | 944 |
| Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | $1.2M | 1 | 614 |
| A Dose Ranging, Multicenter, Sham-Controlled Study to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus | $1.2M | 0 | 199 |
| A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery | $965,041 | 3 | 451 |
| Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty | $782,408 | 3 | 666 |
| A Prospective, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass System, Model iS3, in Subjects with Refractory Glaucoma | $717,203 | 3 | 267 |
| A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA | $530,709 | 0 | 345 |
| iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study | $431,976 | 1 | 152 |
| Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5 | $410,990 | 0 | 500 |
| A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus | $306,630 | 0 | 51 |
| Prospective, Non-Randomized, Open-Label, Multi-Center, Single Arm Study of Exchange of Travoprost Intraocular Implant | $268,256 | 0 | 132 |
| A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1) | $176,655 | 0 | 196 |
| A Prospective, Randomized, Controlled, Comparative Multicenter Clinical Study of Glaukos Trabecular Micro-Bypass System Model iS3 Infinite vs. Hydrus in Adult Subjects With Primary Open-Angle Glaucoma (POAG) | $146,503 | 0 | 14 |
| A Prospective, Randomized, Controlled, Comparative Multicenter Clinical Studyof Glaukos Trabecular Micro-Bypass System Model iS3 Infinite vs. Hydrus in Adult Subjects With Primary Open-Angle Glaucoma (POAG) | $128,111 | 0 | 12 |
| A Phase IV Observational Registry to Assess the Safety and Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery | $94,760 | 0 | 41 |
| Observational Registry to Assess the Durability of Effect of Corneal Colagen Cross-linking | $78,880 | 0 | 49 |
| Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6% and 8% BID for the Treatment of Signs and Symptoms of Dry Eye Disease | $56,898 | 0 | 22 |
| Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4, 6 and 8 BID for the Treatment of Signs and Symptoms of Dry Eye Disease | $56,390 | 0 | 66 |
| Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% | $50,250 | 0 | 11 |
| Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6% and 8% BID for the Treatment of Presbyopia | $39,448 | 0 | 11 |
| A PROSPECTIVE | $37,310 | 0 | 4 |
| An Image Collection Study of Corneal Ulcers in Adult Participants | $28,365 | 0 | 7 |
| Long term safety and effectiveness of corneal collagen cross-linking in eyes with progressive keratoconus and corneal ectasia after refractive surgery | $25,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 7
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Peter Hersh, M.d, M.D | Specialist | Teaneck, NJ | $9,644 | $0 |
| Kanika Agarwal, Md, MD | Ophthalmology | Boston, MA | $9,602 | $0 |
| Dr. H Tanaka, Md, MD | Ophthalmology | San Francisco, CA | $9,443 | $0 |
| John Parker, Md, MD | Ophthalmology | Vestavia, AL | $9,439 | $0 |
| David Vroman, Md, MD | Ophthalmology | Ladson, SC | $9,337 | $0 |
| Dr. James Lehmann, Md, MD | Ophthalmology | San Antonio, TX | $9,281 | $0 |
| Dr. Alex Huang, Md, MD | Ophthalmology | San Diego, CA | $9,207 | $0 |
| Dr. Scott Walsman, Md, MD | Ophthalmology | Jersey City, NJ | $9,183 | $0 |
| Robert Wooldridge, O.d. Pc, O.D. PC | Optometrist | Murray, UT | $9,180 | $0 |
| Dr. Joseph Kavanagh, M.d, M.D | Ophthalmology | Seguin, TX | $9,127 | $0 |
| David Boyer, Md, MD | Ophthalmology | Los Angeles, CA | $9,000 | $0 |
| Dr. Andrew Kao, Md, MD | Ophthalmology | Bakersfield, CA | $8,867 | $0 |
| Neda Shamie, M.d, M.D | Ophthalmology | Los Angeles, CA | $8,774 | $0 |
| Jason Mayer, M.d, M.D | Internal Medicine | Fort Collins, CO | $8,626 | $0 |
| Dr. Nicole Fuerst, M.d, M.D | Cornea and External Diseases Specialist | West Covina, CA | $8,524 | $0 |
| James Lee, Md, MD | Ophthalmology | Colorado Springs, CO | $8,519 | $0 |
| Omar Shoukfeh, Md, MD | Glaucoma Specialist | Lubbock, TX | $8,508 | $0 |
| Dr. Naveen Rao, M.d, M.D | Ophthalmology | Burlington, MA | $8,488 | $0 |
| Emily Schehlein, Md, MD | Ophthalmology | Brighton, MI | $8,282 | $0 |
| Scot Morris, O.d, O.D | Optometrist | Conifer, CO | $8,112 | $0 |
| Dr. Elana Rosenberg | Ophthalmology | New York, NY | $8,106 | $0 |
| Jonathan Ellant | Specialist | Hauppauge, NY | $8,005 | $0 |
| Nitasha Gupta, Md, MD | Internal Medicine | New York, NY | $7,990 | $0 |
| Adam Moss, M.d, M.D | Ophthalmology | Edina, MN | $7,925 | $0 |
| Dr. Michael Saidel, Md, MD | Ophthalmology | Sonoma, CA | $7,871 | $0 |
Ad
Top Products
- ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM $3.5M
- PHOTREXA VISCOUS $2.3M
Associated Products (32)
- ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM $3.5M
- PHOTREXA VISCOUS $2.3M
- iStent Trabecular Micro-Bypass Stent System $2.2M
- iDose $1.8M
- iStent inject Trabecular Micro-Bypass Stent System $1.4M
- iStent inject $1.4M
- G2-TR_iDoseTR $1.4M
- IDOSE TR $1.0M
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS $824,900
- iStent Infinite $693,762
- iSTENT iNJECT TRABECULAR MICRO-BYPASS STENT SYSTEM $635,857
- CE-marked KXLA system $576,090
- KXL system (not refurbished) $492,549
- GS-M-IS_iStent inject Trabecular Micro-Bypass System Model G2-M-IS $490,445
- iAccess Precision Blade $431,454
- ISTENT INJECT W $349,707
- iStent Trabecular Micro-Bypass System Model iS3 $333,404
- iStent infinite Trabecular Micro-Bypass System Model iS3 $329,786
- iStent $307,407
- IACCESS $290,859
- iStent inject W $289,943
- KXL System $215,213
- KXL SYSTEM $154,524
- iDose TR $130,802
- ILINK $104,241
- Radius $99,999
- Preserflo $64,841
- iStent inject Trabecular Micro-Bypass System $31,766
- ISTENT $25,516
- 25357-013-01_Photrexa Viscous and Photrexa $22,395
- PHOTREXA CROSS-LINKING KIT $14,543
- iStent Inject Trabecular Micro-Bypass System $11,352
Payment Categories
- Food & Beverage $3.2M
- Consulting $7.4M
- Travel & Lodging $502,447
- Research $43.5M
- Royalties $693,689
About Glaukos Corporation
Glaukos Corporation has made $60.7M in payments to 17,708 healthcare providers, recorded across 69,190 transactions in the CMS Open Payments database. In 2024, the company paid $11.4M. The top product by payment volume is ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM ($3.5M).
Payments were distributed across 102 medical specialties. The top specialty by payment amount is Ophthalmology ($12.6M to 5,782 doctors).
Payment categories include: Food & Beverage ($3.2M), Consulting ($7.4M), Research ($43.5M), Travel & Lodging ($502,447), Royalties ($693,689).
Glaukos Corporation is associated with 32 products in the CMS Open Payments database, including ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM, PHOTREXA VISCOUS, and iStent Trabecular Micro-Bypass Stent System.